TherapeuticsMD, Inc. Annual Report: A Simple Guide

I’m writing this guide to help you understand how TherapeuticsMD performed this year. Instead of digging through dense legal filings, we’ll break down the company’s health, their wins, their risks, and what the future might look like.

1. What does this company do?

TherapeuticsMD is now a pharmaceutical royalty company. They no longer handle the marketing or sales of their products. Instead, they have handed those rights to partners like Mayne Pharma in the U.S. and Theramex internationally.

The company collects a royalty check—a percentage of sales—whenever these partners sell products like IMVEXXY, BIJUVA, and ANNOVERA. They have moved from running a drug business to acting as a lean manager of these assets.

2. Financial Health: The "Going Concern" Warning

The company issued a "going concern" warning, which means they are not certain they have enough cash to stay in business for the next 12 months.

The company lost about $17.5 million last year and held only $1.6 million in cash at year-end. Because they no longer manufacture or market drugs, their income comes exclusively from royalty checks, which have not been sufficient to cover their debt and operating costs. They have reduced their staff to just one executive and a few consultants to preserve capital. If they need to raise more cash by selling additional shares, they will issue more stock, which reduces your ownership percentage and may lower the value of your shares.

3. The Legal Battle: A Major Distraction

The company is currently involved in litigation with their main partner, Mayne Pharma, regarding their 2023 agreement. The parties disagree on how to calculate payments and rebates, which directly impacts the amount of royalty revenue TherapeuticsMD receives.

While a judge recently recommended dismissing some parts of the lawsuits, other claims remain active. This creates uncertainty regarding the company’s future cash flow, and the ongoing legal fees continue to drain their limited cash reserves.

4. International Expansion

The company maintains deals with Theramex to sell products in Europe and Australia. In late 2024, they transferred their Israeli sales rights to Theramex to simplify their business structure. While these international markets currently represent a small portion of total revenue, they serve as a secondary source of cash for the company.

5. Key Risks

• Survival Risk: With very little cash on hand, the company may run out of money within a year without additional funding or increased royalty income.
• Legal Uncertainty: The lawsuits with Mayne Pharma could result in lower royalty payments and high legal expenses.
• Dependency: Because the company sold its own sales team, it is entirely dependent on the sales performance of its partners.
• Stock Volatility: As a small company, the stock price is susceptible to significant swings based on court filings or minor operational news.
• Debt: The company carries significant debt; an inability to meet these obligations could lead to a default, which would negatively impact shareholders.

Bottom Line: TherapeuticsMD is now a simple royalty-collection business, but they are in a precarious position. The company’s future depends entirely on their partners’ sales performance and the outcome of their legal battles. Given the "going concern" warning and the limited cash on hand, this is a high-risk situation that requires careful monitoring of their ability to maintain operations.